Cargando…
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310389/ https://www.ncbi.nlm.nih.gov/pubmed/32576246 http://dx.doi.org/10.1186/s13075-020-02247-3 |
| _version_ | 1783549359248375808 |
|---|---|
| author | Takeuchi, Tsutomu Tanaka, Yoshiya Tanaka, Sakae Kawakami, Atsushi Song, Yeong-Wook Chen, Yi-Hsing Rokuda, Mitsuhiro Izutsu, Hiroyuki Ushijima, Satoshi Kaneko, Yuichiro Nakashima, Yoshihiro Shiomi, Teruaki Yamada, Emi |
| author_facet | Takeuchi, Tsutomu Tanaka, Yoshiya Tanaka, Sakae Kawakami, Atsushi Song, Yeong-Wook Chen, Yi-Hsing Rokuda, Mitsuhiro Izutsu, Hiroyuki Ushijima, Satoshi Kaneko, Yuichiro Nakashima, Yoshihiro Shiomi, Teruaki Yamada, Emi |
| author_sort | Takeuchi, Tsutomu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7310389 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73103892020-06-23 Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan Takeuchi, Tsutomu Tanaka, Yoshiya Tanaka, Sakae Kawakami, Atsushi Song, Yeong-Wook Chen, Yi-Hsing Rokuda, Mitsuhiro Izutsu, Hiroyuki Ushijima, Satoshi Kaneko, Yuichiro Nakashima, Yoshihiro Shiomi, Teruaki Yamada, Emi Arthritis Res Ther Correction BioMed Central 2020-06-23 2020 /pmc/articles/PMC7310389/ /pubmed/32576246 http://dx.doi.org/10.1186/s13075-020-02247-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Takeuchi, Tsutomu Tanaka, Yoshiya Tanaka, Sakae Kawakami, Atsushi Song, Yeong-Wook Chen, Yi-Hsing Rokuda, Mitsuhiro Izutsu, Hiroyuki Ushijima, Satoshi Kaneko, Yuichiro Nakashima, Yoshihiro Shiomi, Teruaki Yamada, Emi Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title | Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title_full | Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title_fullStr | Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title_full_unstemmed | Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title_short | Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| title_sort | correction to: safety and effectiveness of peficitinib (asp015k) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in japan, korea, and taiwan |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310389/ https://www.ncbi.nlm.nih.gov/pubmed/32576246 http://dx.doi.org/10.1186/s13075-020-02247-3 |
| work_keys_str_mv | AT takeuchitsutomu correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT tanakayoshiya correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT tanakasakae correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT kawakamiatsushi correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT songyeongwook correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT chenyihsing correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT rokudamitsuhiro correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT izutsuhiroyuki correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT ushijimasatoshi correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT kanekoyuichiro correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT nakashimayoshihiro correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT shiomiteruaki correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan AT yamadaemi correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan |